Eleva, a manufacturer of superior biologics, is entering clinical phases with its own drug candidates, such as immune-regulating factor H, as well as in collaboration with pharmaceutical partners. Its moss-based platform is ideally suited to produce difficult-to-express but therapeutically promising drug candidates.

Its recently expanded production capacity enables Eleva to conduct clinical studies of its drug candidates. Among the first ones is factor H which will be developed all the way through phase II. Up to 2,500 l will be produced in state-of-the-art single-use reactors with improved LED technology at a GMP site. Eleva’s moss-based platform offers unique advantages for recombinant protein development, such as:

• Moss glycostructure naturally lacks core α-1,3 fucose – a known allergen – while any other glycans can be “humanized”. This leads to excellent organ uptake, as demonstrated in clinical studies.
• Being a plant, it will not be contaminated with animal pathogens, which eliminates the need for antibiotics.
• The moss production system, haploid by nature, is based on an intact organism, not on cell cultures. This guarantees exceptionally reliable and stable modifications.

Eleva is leveraging those inherent advantages to produce complex proteins for future therapies, such as 2nd generation oncological therapeutics, or virus-like-particles (VLP) for vaccine development.